Drug Manufacturing

Samsung Biologics reveals plans to add mRNA vaccine production line

South Korean drug manufacturer Samsung Biologics is planning to expand its portfolio of services by adding a mRNA vaccine drug substance (DS) manufacturing line at its facility in Songdo, Seoul.

CANbridge signs license agreement with Mirum for maralixibat in Greater China

Biopharmaceutical company CANbridge Pharmaceuticals has signed a licensing agreement with Mirum Pharmaceuticals for the development and commercialisation of maralixibat in Greater China.

GSK and Vir announce EMA review of VIR-7831 for early treatment of Covid-19

GlaxoSmithKline and Vir Biotechnology have announced the European Medicines Agency (EMA) review of VIR-7831 (GSK4182136) for the early treatment of Covid-19.

Takeda Pharmaceutical concludes sale of OTC and non-core assets to Orifarm for $670m

Takeda Pharmaceutical Company has completed the previously announced sale of a portfolio of select over-the-counter (OTC) pharma products and non-core assets to Orifarm Group for $670m.

Fidia Farmaceutici acquires Sanofi’s anti-inflammatory drugs portfolio

Italian pharmaceutical company Fidia Farmaceutici has signed a binding agreement to acquire an integrated portfolio of anti-inflammatory drugs from Sanofi.

USFDA approves Janssen’s PONVORY for treatment of multiple sclerosis

Johnson & Johnson’s Janssen Pharmaceutical Companies have announced the US Food and Drug Administration (FDA) approval of PONVORY for the treatment of relapsing forms of multiple sclerosis (MS) in adults.

Boston Pharmaceuticals signs three-year agreement with GSK

The US-based clinical stage biopharmaceutical company Boston Pharmaceuticals has announced the signing of a unique three-year out-license and option agreement with the UK-based GlaxoSmithKline (GSK).

Ambrx gets orphan drug designation for gastric cancer treatment ARX788

The US Food and Drug Administration (FDA) grants orphan drug designation to Ambrx for ARX788, a homogeneous and highly stable antibody drug conjugate, for the treatment of HER2-positive gastric cancer.

Enveric Biosciences signs licensing agreement with Diverse Biotech

Enveric Biosciences has announced that it has signed an exclusive, perpetual licensing agreement with Diverse Biotech to develop new molecules for the treatment of cancer and other debilitating diseases.